Navigation Links
TransGenRx Protein Therapeutics Technology to Support Research Related to Protein-Based HDL Therapies at Esperion Therapeutics
Date:6/21/2010

PLYMOUTH, Mich. and BATON ROUGE, La., June 21 /PRNewswire/ -- Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that TransGenRx, a global leader in transgenic technology, will produce protein-based therapeutics to be used in the company's research efforts targeting HDL therapies for the treatment of cardio-metabolic disease. Under the terms of the agreement, TransGenRx will coordinate production of protein-based therapies for a range of research needs using a proprietary expression system.

Researchers at Esperion are working to develop novel therapies to treat cardio-metabolic disease including therapies based on HDL, the body's "good" cholesterol, which has been shown to play an important role in lipid management. The company's development platform includes therapies designed to mimic or enhance the function of HDL in managing and removing cholesterol and other lipids from atherosclerotic plaques. Researchers at Esperion have initiated preclinical and clinical research related to a variety of pathways for better lipid regulation to treat the full spectrum of cardio-metabolic diseases, from early risk factors to acute coronary syndromes and atherosclerosis.

"While HDL continues to show great promise in the treatment of cardiovascular disease, there have been significant challenges in the development of protein-based drug therapies. By working with the outstanding research and technology team at TransGenRx, we are positioned to access one of the most advanced, cost-effective protein expression technologies in the world to supply the protein-based therapies we will use in our research," said Roger Newton, Ph.D., President and CEO of Esperion. "This collaboration represents a tremendous advantage in our efforts to identify and access complex protein-based therapies that will lead to new treatments for cardio-metabolic disease in the years ahead."

On June 14, 2010, Esperion announced the establishment of a collaborative research agreement with the Cleveland Clinic Foundation, one of the world's leading academic medical centers. In this collaboration teams at Esperion and Cleveland Clinic are working to advance research involving HDL mimetics and other protein-based therapies to treat cardiovascular disease.

"In terms of both cost and complexity, the development of protein-based therapies requires broad expertise and targeted, advanced technology to be successful. At TransGenRx, our proprietary protein expression technology is uniquely suited to meet the key challenges in the production of therapeutic proteins, and we look forward to supporting the important work by the teams at Esperion and Cleveland Clinic in efforts to develop promising new HDL therapies," said Richard Cooper, Ph.D., Executive Vice President and Chief Scientific Officer of TransGenRx.

About TransGenRx

TransGenRx, a bio-pharmaceutical manufacturing company, has developed technology that significantly reduces the cost of producing protein-based drugs by using a high expressing avian cell line combined with a patented vector system. Patented and patent-pending processes allow TransGenRx to develop custom proteins to meet a wide range of specifications. The company's core technology involves the targeted integration of a desired gene sequence into virtually any animal or cell culture system and the controlled expression of that sequence to achieve a desired outcome (protein production, gene therapy, etc.) The Louisiana State University Agricultural Center has had an established research relationship with TransGenRx since 2002. For information visit www.tgrxinc.com.

About Esperion Therapeutics

Esperion Therapeutics, Inc., located in Plymouth, Michigan, discovers and develops novel therapies for the treatment of cardiovascular and metabolic diseases. The company is funded by top tier venture capital investors, including Aisling Capital, Alta Partners, Arboretum Ventures, Asset Management Company and Domain Associates. For more information please visit www.esperion.com.


'/>"/>
SOURCE Esperion Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Althea Technologies Acquires Altus Pharmaceuticals(R) Assets and IP Portfolio, Establishing Technology Platform for Protein Formulations.
2. California Natural Products Unveils CalNaturale(TM) Svelte(TM) All-Natural Sustained Energy Protein Drink
3. Bone Biologics Announces Another Major US Patent Issuance for Recombinant Protein Process
4. Repligen Receives Notice of Allowance for Recombinant Protein A Patent
5. Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A
6. ForteBio Launches New Dip and Read(TM) Residual Protein A Detection Kit; Introduces Sidekick(TM) Offline Biosensor Immobilization Station for All Octet(R) Instruments
7. Fate Therapeutics iPSC Technology Awarded Top Industry Honors for Small Molecule and Protein Reprogramming Breakthroughs
8. Pfenex Grants Exclusive License to Merck & Co., Inc. for the Production of Proteins for Undisclosed Vaccine Program
9. Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds
10. Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein
11. ZyStor Therapeutics, Inc. Cleared to Begin Clinical Trial for Targeted Protein Therapeutic for the Treatment of Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... YORK , February 23, 2017 ... in the United States . According to ... the cannabis industry is expected to create 283,422 jobs by ... percent compounded over the next four years. The accelerating pace ... drives the growth of legal cannabis market, which will further ...
(Date:2/23/2017)... York , February 23, 2017 ... Holter Monitor Market are GE Healthcare, Koninklijke Philips N.V., ... about 48% in the global market in 2015. Strong ... two key factors assessed to be aiding these players ... Research states that the players in the global market ...
(Date:2/23/2017)... 2017   SeraCare Life Sciences , a ... diagnostics manufacturers and clinical laboratories, is announcing an ... NGS-Based Tests" to be hosted by GenomeWeb ... Eastern Standard Time (US). The goal ... for improved performance and global standardization in the ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... , ... Hamlin Dental Group and Dr. Hamid Reza, dentist in North ... month of February, patients who visit Hamlin Dental Group will receive a ticket for ... at the Cheesecake Factory. , Tickets are available for routine dental visits and ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, ... symposium on “Doping in Sport: How the Culture Might Change,” in ... LLP. The symposium will be held at Pepperdine University in Malibu, California. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a global data and ... Premier Research, a leading clinical development service provider, has selected ERT’s Trial Oversight ... due in part to an array of circumstances including the use of multiple ...
(Date:2/23/2017)... Lincoln, RI (PRWEB) , ... February 23, 2017 ... ... announced today a new partnership with the Rhode Island Consortium for Autism Research ... provide an opportunity for children with autism spectrum disorder (ASD) to see films ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Top cosmetic and ... Patriot program today with a new Indiegogo campaign . Individuals are now ... veterans in the Los Angeles area, either as a participating patient or through an ...
Breaking Medicine News(10 mins):